Criteria for oral appliance and/or supine avoidance therapy selection based on outcome optimization and cost-effectiveness
J Med Econ. 2021 May 14:1. doi: 10.1080/13696998.2021.1930549. Online ahead of print.ABSTRACTAim: Produce empirical support for further enhancements to a therapy selection protocol for obstructive sleep apnea (OSA) patients intolerant of positive airway pressure.Methods: A retrospective analysis was conducted in 101 men and 69 women patients. Two-night home sleep apnea studies were conducted at baseline and with a trial oral appliance. Twenty-minutes in-position sleep was required to compute supine and non-supine apnea-hypopnea indexes (AHI). Data analyses were applied after stratification by sex and response to oral appli...
Source: Journal of Medical Economics - May 15, 2021 Category: Health Management Authors: Daniel J Levendowski Richard Olmstead Edward Sall Philip R Westbrook Bretton Beine Dominic Munafo Source Type: research

Economic evaluation of home medication review by community pharmacists (HMR-CP) for patients with type 2 diabetes mellitus (T2DM)
Conclusion: HMR-CP was a cost-effective intervention that had significantly reduced the HbA1c among the T2DM patients, although associated with higher mean total costs per participant.PMID:33989086 | DOI:10.1080/13696998.2021.1889573 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 14, 2021 Category: Health Management Authors: Mohd Rozaini Rosli David Bin-Chia Wu Chin Fen Neoh Mahmathi Karuppannan Source Type: research

Modelling the value of innovative treatments for Alzheimer's disease in the United States
J Med Econ. 2021 May 14:1. doi: 10.1080/13696998.2021.1927747. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is the predominant cause of dementia and a leading cause of death globally. With no cure or treatment to slow disease progression, AD-related healthcare costs are substantial and increase as the severity of the disease progresses. Given the complexity of this disease, including initial pathophysiological damage occurring decades before clinical manifestation, finding new impactful treatments for AD relies on highly innovative research and development. However, such sizable and sustained investments bring in...
Source: Journal of Medical Economics - May 14, 2021 Category: Health Management Authors: Charles Makin Peter Neumann Sue Peschin Dana Goldman Source Type: research

Cost-effectiveness of defibrotide for treatment of severe veno-occlusive disease: It is time for evidence based economic evaluations
J Med Econ. 2021 May 12:1. doi: 10.1080/13696998.2021.1929259. Online ahead of print.NO ABSTRACTPMID:33979234 | DOI:10.1080/13696998.2021.1929259 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 12, 2021 Category: Health Management Authors: Alois Gratwohl Source Type: research

Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden
Conclusions PR-fampridine represents a cost-effective treatment for MS-related walking impairment in Sweden, due to improvements in patients' quality of life and reduced healthcare resource utilization.PMID:33966549 | DOI:10.1080/13696998.2021.1927746 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 10, 2021 Category: Health Management Authors: C Acosta M Gianinazzi T Dort N Armstrong S Ryder T Lundqvist M Ekelund J Lycke Source Type: research

The health economic impact of varying levels of adherence to colorectal screening on providers and payers
CONCLUSIONS: Among all adherence scenarios, perspectives, and age ranges, increased mt-sDNA utilization yielded cost-savings.PMID:33970747 | DOI:10.1080/13696998.2020.1858607 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 10, 2021 Category: Health Management Authors: Joanne M Hathway Lesley-Ann Miller-Wilson Weiyu Yao Ivar S Jensen Milton C Weinstein Philip D Parks Source Type: research

Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden
Conclusions PR-fampridine represents a cost-effective treatment for MS-related walking impairment in Sweden, due to improvements in patients' quality of life and reduced healthcare resource utilization.PMID:33966549 | DOI:10.1080/13696998.2021.1927746 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 10, 2021 Category: Health Management Authors: C Acosta M Gianinazzi T Dort N Armstrong S Ryder T Lundqvist M Ekelund J Lycke Source Type: research

The health economic impact of varying levels of adherence to colorectal screening on providers and payers
CONCLUSIONS: Among all adherence scenarios, perspectives, and age ranges, increased mt-sDNA utilization yielded cost-savings.PMID:33970747 | DOI:10.1080/13696998.2020.1858607 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 10, 2021 Category: Health Management Authors: Joanne M Hathway Lesley-Ann Miller-Wilson Weiyu Yao Ivar S Jensen Milton C Weinstein Philip D Parks Source Type: research

Healthcare resource use and indirect costs associated with migraine in Italy: results from the < em > My Migraine Voice < /em > survey
CONCLUSION: Migraine-related HRU and indirect costs are high among individuals with ≥4 MMDs (particularly those with ≥2 TF). There is a need for more effective treatments and better management of migraine to reduce the functional and economic burden among this difficult-to-treat population.PMID:33955821 | DOI:10.1080/13696998.2021.1925557 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 6, 2021 Category: Health Management Authors: Paolo Martelletti Todd J Schwedt Pamela Vo Daniela Ritrovato Margaret C Reilly Mariantonietta Naclerio Pallavi Ranjan Joern Kleebach Parth Joshi Source Type: research

Continuity and change in the pharmaceutical supply chain: actors, actions, and aversions
CONCLUSIONS: Organizational, operational, and value-adding measures to overhaul the drug supply chain and make it perform better have been proposed in the surveyed literature and elsewhere. Yet, aspects of the supply chain that bear a direct impact on firm short-term financial success typically assume precedence in evaluations of performance and effectiveness. Whether and how well the drug supply chain will change to cope and adapt to the major challenges and upheavals it currently faces are lingering questions.PMID:33941029 | DOI:10.1080/13696998.2021.1925123 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 4, 2021 Category: Health Management Authors: Roger Lee Mendoza Source Type: research

Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population
J Med Econ. 2021 Apr 29:1. doi: 10.1080/13696998.2021.1915627. Online ahead of print.ABSTRACTAIM: To assess the real-world healthcare resource utilization (HRU) and costs of patients with non-valvular atrial fibrillation (NVAF) and obesity newly initiated on rivaroxaban or warfarin in the United States (US).METHODS: This retrospective study used IQVIA PharMetrics® Plus data (01/2010-09/2019) to evaluate patients (≥ 18 years) with NVAF and obesity (body mass index ≥30 kg/m2) initiated on rivaroxaban or warfarin (on or after 01/2013). Inverse probability of treatment weighting (IPTW) was used to adjust for confound...
Source: Journal of Medical Economics - April 29, 2021 Category: Health Management Authors: Jeffrey S Berger Fran çois Laliberté Akshay Kharat Dominique Lejeune Kenneth Todd Moore Young Jung Patrick Lefebvre Veronica Ashton Source Type: research

Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population
CONCLUSION: Comparisons of the effectiveness and benefits of specific CRC screening strategies should include both test-specific performance characteristics and real-world adherence to screening tests and, when indicated, follow-up colonoscopy.PMID:33902366 | DOI:10.1080/13696998.2021.1922240 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Deborah A Fisher Jordan J Karlitz Sushanth Jeyakumar Nathaniel Smith Paul Limburg David Lieberman A Mark Fendrick Source Type: research

Burden of illness among Medicare and Non-Medicare US populations with acquired thrombotic thrombocytopenic purpura
CONCLUSION: This is the first real-world study evaluating burden of illness among aTTP patients in the US across payer types. Despite being treated with TPE, patients with aTTP have lower survival rates in comparison to a matched cohort without aTTP. These findings highlight the need for more effective and novel therapies to reduce disease burden for this population.Key PointsIn US Medicare and managed care populations with aTTP between 2010-2018, aTTP can lead to significant utilization of ICU services due to clinical complications, and/or relapse following hospital dischargeDespite treatment with therapeutic plasma excha...
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Laurence Pollissard Anne Shah Rajeshwari S Punekar Allison Petrilla Huy P Pham Source Type: research

Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: A budget impact analysis on the basis of clinical trial and real-world data
CONCLUSIONS: The introduction of a new pegfilgrastim biosimilar (NYVEPRIA®) is potentially associated with substantial cost savings for French healthcare system.PMID:33904357 | DOI:10.1080/13696998.2021.1922252 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Jingyan Yang Rongzhe Liu Anna Granghaud Omer Zaidi Jennifer Stephens Source Type: research

Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective
CONCLUSIONS: TIS for treating r/r DLBCL patients who have failed ≥2 lines of systemic therapies, is likely to be cost effective with limited budget impact.PMID:33904359 | DOI:10.1080/13696998.2021.1922066 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Xiao Jun Wang Yi-Ho Wang Shing Chau Tony Li Christina Gkitzia Soon Thye Lim Liang Piu Koh Francesca Lorraine Wei Inng Lim William Ying Khee Hwang Source Type: research

Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population
CONCLUSION: Comparisons of the effectiveness and benefits of specific CRC screening strategies should include both test-specific performance characteristics and real-world adherence to screening tests and, when indicated, follow-up colonoscopy.PMID:33902366 | DOI:10.1080/13696998.2021.1922240 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Deborah A Fisher Jordan J Karlitz Sushanth Jeyakumar Nathaniel Smith Paul Limburg David Lieberman A Mark Fendrick Source Type: research

Burden of illness among Medicare and Non-Medicare US populations with acquired thrombotic thrombocytopenic purpura
CONCLUSION: This is the first real-world study evaluating burden of illness among aTTP patients in the US across payer types. Despite being treated with TPE, patients with aTTP have lower survival rates in comparison to a matched cohort without aTTP. These findings highlight the need for more effective and novel therapies to reduce disease burden for this population.Key PointsIn US Medicare and managed care populations with aTTP between 2010-2018, aTTP can lead to significant utilization of ICU services due to clinical complications, and/or relapse following hospital dischargeDespite treatment with therapeutic plasma excha...
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Laurence Pollissard Anne Shah Rajeshwari S Punekar Allison Petrilla Huy P Pham Source Type: research

Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: A budget impact analysis on the basis of clinical trial and real-world data
CONCLUSIONS: The introduction of a new pegfilgrastim biosimilar (NYVEPRIA®) is potentially associated with substantial cost savings for French healthcare system.PMID:33904357 | DOI:10.1080/13696998.2021.1922252 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Jingyan Yang Rongzhe Liu Anna Granghaud Omer Zaidi Jennifer Stephens Source Type: research

Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective
CONCLUSIONS: TIS for treating r/r DLBCL patients who have failed ≥2 lines of systemic therapies, is likely to be cost effective with limited budget impact.PMID:33904359 | DOI:10.1080/13696998.2021.1922066 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Xiao Jun Wang Yi-Ho Wang Shing Chau Tony Li Christina Gkitzia Soon Thye Lim Liang Piu Koh Francesca Lorraine Wei Inng Lim William Ying Khee Hwang Source Type: research

Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population
CONCLUSION: Comparisons of the effectiveness and benefits of specific CRC screening strategies should include both test-specific performance characteristics and real-world adherence to screening tests and, when indicated, follow-up colonoscopy.PMID:33902366 | DOI:10.1080/13696998.2021.1922240 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 27, 2021 Category: Health Management Authors: Deborah A Fisher Jordan J Karlitz Sushanth Jeyakumar Nathaniel Smith Paul Limburg David Lieberman A Mark Fendrick Source Type: research

Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event
J Med Econ. 2021 Apr 26:1. doi: 10.1080/13696998.2021.1922195. Online ahead of print.ABSTRACTAIMS: The study compared quality outcomes, resource utilization, and costs in Medicare beneficiaries with chronic heart failure with reduced ejection fraction (HFrEF) with and without a worsening heart failure event (WHFE).METHODS: This retrospective observational study evaluated claims data for two cohorts of Medicare beneficiaries with chronic HFrEF who were enrolled in Medicare Fee-For-Service (FFS) or Medicare Advantage (MA) plans. The index date was the first claim of HFrEF between October 2015-September 2017. Patients with WH...
Source: Journal of Medical Economics - April 26, 2021 Category: Health Management Authors: Robert J Mentz Zulkarnain Pulungan Seung Kim Mei Yang Christie Teigland Robert Hilkert Laurence M Djatche Source Type: research

The tyranny of the SW quadrant
J Med Econ. 2021 Apr 26:1. doi: 10.1080/13696998.2021.1922210. Online ahead of print.NO ABSTRACTPMID:33900900 | DOI:10.1080/13696998.2021.1922210 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 26, 2021 Category: Health Management Authors: Panayiotis Petrou Source Type: research

Is there a correlation between total fertility rate, utilization of assisted reproduction technology and national wealth in Europe?
Conclusions There is a strong correlation across Europe between GDP and utilization of ART. This correlation does not exist within the developed economies. In Europe the utilization of ART treatment is dependent on national wealth and not on the TFR in the country.PMID:33879012 | DOI:10.1080/13696998.2021.1917863 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Amir Lass Geffen Lass Source Type: research

Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants
J Med Econ. 2021 Apr 21:1. doi: 10.1080/13696998.2021.1918922. Online ahead of print.ABSTRACTAIM: We aimed to determine the incidence of and identify the factors associated with treatment-resistant depression (TRD), psychiatric conditions, hospitalization, and cost in patients with major depressive disorder (MDD) who were treated using second-line strategies after an inadequate response to initial antidepressants (AD).MATERIALS AND METHODS: Using South Korean National Health Insurance claims data (January 1, 2013 to June 30, 2018), we conducted a retrospective cohort analysis in newly treated patients with MDD who subseque...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: HyeJin Park Chan Mi Park Jong-Min Woo Ju-Young Shin Eui-Kyung Lee Sun-Hong Kwon Source Type: research

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database
J Med Econ. 2021 Apr 20:1. doi: 10.1080/13696998.2021.1917421. Online ahead of print.ABSTRACTINTRODUCTION: This US claims-based study aimed to identify and characterize temporal trends in diagnostic pathways for patients likely to have neuromyelitis optica spectrum disorder (NMOSD).METHODS: Patients were identified from IBM MarketScan Commercial Databases if, within 1 year, they had 2 NMOSD claims separated by ≥60 days; 2 transverse myelitis (TM) or optic neuritis (ON) claims separated by ≥60 days and 1 additional symptom (TM, ON or area postrema syndrome); or 1 NMOSD claim and 1 additional symptom. The first NMOSD o...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Alex Exuzides Ning Wu Daniel Sheinson Carlos Flores Avile Cristina Costantino Paris Sidiropoulos Source Type: research

Is there a correlation between total fertility rate, utilization of assisted reproduction technology and national wealth in Europe?
Conclusions There is a strong correlation across Europe between GDP and utilization of ART. This correlation does not exist within the developed economies. In Europe the utilization of ART treatment is dependent on national wealth and not on the TFR in the country.PMID:33879012 | DOI:10.1080/13696998.2021.1917863 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Amir Lass Geffen Lass Source Type: research

Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants
J Med Econ. 2021 Apr 21:1. doi: 10.1080/13696998.2021.1918922. Online ahead of print.ABSTRACTAIM: We aimed to determine the incidence of and identify the factors associated with treatment-resistant depression (TRD), psychiatric conditions, hospitalization, and cost in patients with major depressive disorder (MDD) who were treated using second-line strategies after an inadequate response to initial antidepressants (AD).MATERIALS AND METHODS: Using South Korean National Health Insurance claims data (January 1, 2013 to June 30, 2018), we conducted a retrospective cohort analysis in newly treated patients with MDD who subseque...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: HyeJin Park Chan Mi Park Jong-Min Woo Ju-Young Shin Eui-Kyung Lee Sun-Hong Kwon Source Type: research

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database
J Med Econ. 2021 Apr 20:1. doi: 10.1080/13696998.2021.1917421. Online ahead of print.ABSTRACTINTRODUCTION: This US claims-based study aimed to identify and characterize temporal trends in diagnostic pathways for patients likely to have neuromyelitis optica spectrum disorder (NMOSD).METHODS: Patients were identified from IBM MarketScan Commercial Databases if, within 1 year, they had 2 NMOSD claims separated by ≥60 days; 2 transverse myelitis (TM) or optic neuritis (ON) claims separated by ≥60 days and 1 additional symptom (TM, ON or area postrema syndrome); or 1 NMOSD claim and 1 additional symptom. The first NMOSD o...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Alex Exuzides Ning Wu Daniel Sheinson Carlos Flores Avile Cristina Costantino Paris Sidiropoulos Source Type: research

Is there a correlation between total fertility rate, utilization of assisted reproduction technology and national wealth in Europe?
Conclusions There is a strong correlation across Europe between GDP and utilization of ART. This correlation does not exist within the developed economies. In Europe the utilization of ART treatment is dependent on national wealth and not on the TFR in the country.PMID:33879012 | DOI:10.1080/13696998.2021.1917863 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Amir Lass Geffen Lass Source Type: research

Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants
J Med Econ. 2021 Apr 21:1. doi: 10.1080/13696998.2021.1918922. Online ahead of print.ABSTRACTAIM: We aimed to determine the incidence of and identify the factors associated with treatment-resistant depression (TRD), psychiatric conditions, hospitalization, and cost in patients with major depressive disorder (MDD) who were treated using second-line strategies after an inadequate response to initial antidepressants (AD).MATERIALS AND METHODS: Using South Korean National Health Insurance claims data (January 1, 2013 to June 30, 2018), we conducted a retrospective cohort analysis in newly treated patients with MDD who subseque...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: HyeJin Park Chan Mi Park Jong-Min Woo Ju-Young Shin Eui-Kyung Lee Sun-Hong Kwon Source Type: research

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database
J Med Econ. 2021 Apr 20:1. doi: 10.1080/13696998.2021.1917421. Online ahead of print.ABSTRACTINTRODUCTION: This US claims-based study aimed to identify and characterize temporal trends in diagnostic pathways for patients likely to have neuromyelitis optica spectrum disorder (NMOSD).METHODS: Patients were identified from IBM MarketScan Commercial Databases if, within 1 year, they had 2 NMOSD claims separated by ≥60 days; 2 transverse myelitis (TM) or optic neuritis (ON) claims separated by ≥60 days and 1 additional symptom (TM, ON or area postrema syndrome); or 1 NMOSD claim and 1 additional symptom. The first NMOSD o...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Alex Exuzides Ning Wu Daniel Sheinson Carlos Flores Avile Cristina Costantino Paris Sidiropoulos Source Type: research

Is there a correlation between total fertility rate, utilization of assisted reproduction technology and national wealth in Europe?
Conclusions There is a strong correlation across Europe between GDP and utilization of ART. This correlation does not exist within the developed economies. In Europe the utilization of ART treatment is dependent on national wealth and not on the TFR in the country.PMID:33879012 | DOI:10.1080/13696998.2021.1917863 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Amir Lass Geffen Lass Source Type: research

Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants
J Med Econ. 2021 Apr 21:1. doi: 10.1080/13696998.2021.1918922. Online ahead of print.ABSTRACTAIM: We aimed to determine the incidence of and identify the factors associated with treatment-resistant depression (TRD), psychiatric conditions, hospitalization, and cost in patients with major depressive disorder (MDD) who were treated using second-line strategies after an inadequate response to initial antidepressants (AD).MATERIALS AND METHODS: Using South Korean National Health Insurance claims data (January 1, 2013 to June 30, 2018), we conducted a retrospective cohort analysis in newly treated patients with MDD who subseque...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: HyeJin Park Chan Mi Park Jong-Min Woo Ju-Young Shin Eui-Kyung Lee Sun-Hong Kwon Source Type: research

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database
J Med Econ. 2021 Apr 20:1. doi: 10.1080/13696998.2021.1917421. Online ahead of print.ABSTRACTINTRODUCTION: This US claims-based study aimed to identify and characterize temporal trends in diagnostic pathways for patients likely to have neuromyelitis optica spectrum disorder (NMOSD).METHODS: Patients were identified from IBM MarketScan Commercial Databases if, within 1 year, they had 2 NMOSD claims separated by ≥60 days; 2 transverse myelitis (TM) or optic neuritis (ON) claims separated by ≥60 days and 1 additional symptom (TM, ON or area postrema syndrome); or 1 NMOSD claim and 1 additional symptom. The first NMOSD o...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Alex Exuzides Ning Wu Daniel Sheinson Carlos Flores Avile Cristina Costantino Paris Sidiropoulos Source Type: research

Is there a correlation between total fertility rate, utilization of assisted reproduction technology and national wealth in Europe?
Conclusions There is a strong correlation across Europe between GDP and utilization of ART. This correlation does not exist within the developed economies. In Europe the utilization of ART treatment is dependent on national wealth and not on the TFR in the country.PMID:33879012 | DOI:10.1080/13696998.2021.1917863 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Amir Lass Geffen Lass Source Type: research

Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants
J Med Econ. 2021 Apr 21:1. doi: 10.1080/13696998.2021.1918922. Online ahead of print.ABSTRACTAIM: We aimed to determine the incidence of and identify the factors associated with treatment-resistant depression (TRD), psychiatric conditions, hospitalization, and cost in patients with major depressive disorder (MDD) who were treated using second-line strategies after an inadequate response to initial antidepressants (AD).MATERIALS AND METHODS: Using South Korean National Health Insurance claims data (January 1, 2013 to June 30, 2018), we conducted a retrospective cohort analysis in newly treated patients with MDD who subseque...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: HyeJin Park Chan Mi Park Jong-Min Woo Ju-Young Shin Eui-Kyung Lee Sun-Hong Kwon Source Type: research

Identification and temporal trends of patients with neuromyelitis optica spectrum disorder in a US insurance claims database
J Med Econ. 2021 Apr 20:1. doi: 10.1080/13696998.2021.1917421. Online ahead of print.ABSTRACTINTRODUCTION: This US claims-based study aimed to identify and characterize temporal trends in diagnostic pathways for patients likely to have neuromyelitis optica spectrum disorder (NMOSD).METHODS: Patients were identified from IBM MarketScan Commercial Databases if, within 1 year, they had 2 NMOSD claims separated by ≥60 days; 2 transverse myelitis (TM) or optic neuritis (ON) claims separated by ≥60 days and 1 additional symptom (TM, ON or area postrema syndrome); or 1 NMOSD claim and 1 additional symptom. The first NMOSD o...
Source: Journal of Medical Economics - April 21, 2021 Category: Health Management Authors: Alex Exuzides Ning Wu Daniel Sheinson Carlos Flores Avile Cristina Costantino Paris Sidiropoulos Source Type: research

Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: Results from the LIBERTY 360 ° trial
J Med Econ. 2021 Apr 18:1. doi: 10.1080/13696998.2021.1917141. Online ahead of print.ABSTRACTBackground: Multiple studies have demonstrated the high economic burden related to the management of lower extremity peripheral artery disease (PAD). This is the first study to examine long-term PAD-related costs among unselected patients undergoing endovascular intervention, and to investigate how clinical and anatomic factors impact cost outcomes over time.Methods and Results: We performed a prospective health economic study alongside the LIBERTY 360° trial (ClinicalTrials.gov; identifier NCT01855412) - a prospective, multi-c...
Source: Journal of Medical Economics - April 19, 2021 Category: Health Management Authors: Elizabeth A Magnuson Haiyan Li Katherine Vilain Ehrin J Armstrong Eric A Secemsky Stefanos Giannopoulos George L Adams Jihad Mustapha David J Cohen LIBERTY 360 ° Trial Investigators Source Type: research

Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer
CONCLUSIONS: Pembrolizumab is a highly cost-effective treatment option when compared with chemotherapy for women with previously treated dMMR/MSI-H unresectable or mEC. Results were robust to the changes in parameters and assumptions explored.PMID:33866938 | DOI:10.1080/13696998.2021.1917140 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 19, 2021 Category: Health Management Authors: Elizabeth Thurgar Mark Gouldson Suzette Matthijsse Mayur Amonkar Patricia Marinello Navneet Upadhyay Chizoba Nwankwo Raquel Aguiar-Ib áñez Source Type: research